secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRISPR Therapeutics AG (CRSP)
CIK:        0001674416
Form:       8-K
Filed at:   2023-11-16T23:59:59+00:00
Accession:  0000950170-23-064341
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

CRISPR/VERTEX get UK conditional approval for CASGEVY in sickle cell & beta thalassemia
--------------------------------------------------------------------------------

- CASGEVY (exagamglogene autotemcel) received conditional marketing authorization from UK MHRA.
- Approved for patients 12+ with sickle cell disease with recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia.
- Authorization requires no human leukocyte antigen matched related donor; valid for one year, renewable annually.
- CRISPR and partner Vertex jointly developed the CRISPR/Cas9 gene-edited therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674416/000095017023064341/0000950170-23-064341-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674416/000095017023064341/crsp-20231115.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-064341

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer